WO2007021970A3 - Stable pharmaceutical formulations and methods of use thereof - Google Patents

Stable pharmaceutical formulations and methods of use thereof Download PDF

Info

Publication number
WO2007021970A3
WO2007021970A3 PCT/US2006/031439 US2006031439W WO2007021970A3 WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3 US 2006031439 W US2006031439 W US 2006031439W WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pharmaceutical formulations
pharmaceutically active
stable pharmaceutical
pharmaceutical compositions
Prior art date
Application number
PCT/US2006/031439
Other languages
French (fr)
Other versions
WO2007021970A2 (en
Inventor
Heow Meng Tan
Ming Ye
Thomas F Mcgrath
Kevin A Johnston
Maria Micalizzi
Patrick Mckenna
Martin Patrick Redmon
Murali K Vuppala
Gary F Musso
Original Assignee
Praecis Pharm Inc
Heow Meng Tan
Ming Ye
Thomas F Mcgrath
Kevin A Johnston
Maria Micalizzi
Patrick Mckenna
Martin Patrick Redmon
Murali K Vuppala
Gary F Musso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharm Inc, Heow Meng Tan, Ming Ye, Thomas F Mcgrath, Kevin A Johnston, Maria Micalizzi, Patrick Mckenna, Martin Patrick Redmon, Murali K Vuppala, Gary F Musso filed Critical Praecis Pharm Inc
Publication of WO2007021970A2 publication Critical patent/WO2007021970A2/en
Publication of WO2007021970A3 publication Critical patent/WO2007021970A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

The present invention provides pharmaceutical formulations characterized by improved stability of the pharmaceutically active compounds contained therein, methods for preparing the same, and methods of use thereof. The pharmaceutical compositions of the present invention comprise a stable water-insoluble complex of a pharmaceutically active compound and a carrier macromolecule. The advantages of the pharmaceutical compositions of the invention include, for example, the increased stability of a pharmaceutically active compound contained therein.
PCT/US2006/031439 2005-08-15 2006-08-14 Stable pharmaceutical formulations and methods of use thereof WO2007021970A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70853605P 2005-08-15 2005-08-15
US60/708,536 2005-08-15
US73254505P 2005-11-02 2005-11-02
US60/732,545 2005-11-02
US79855506P 2006-05-08 2006-05-08
US60/798,555 2006-05-08

Publications (2)

Publication Number Publication Date
WO2007021970A2 WO2007021970A2 (en) 2007-02-22
WO2007021970A3 true WO2007021970A3 (en) 2008-10-09

Family

ID=37667924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031439 WO2007021970A2 (en) 2005-08-15 2006-08-14 Stable pharmaceutical formulations and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2007021970A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (en) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
DE102007003765A1 (en) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmaceutical composition for the treatment of incontinence
EP2170362B1 (en) 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
CN102697733B (en) * 2007-12-04 2015-08-12 上海抗体药物国家工程研究中心有限公司 A kind of interior parcel immunotoxin connects the Poly(D,L-lactide-co-glycolide nano-particle of antibody outward
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN101810583B (en) * 2010-04-09 2013-09-11 佟丽 HIV (Human Immunodeficiency Virus) fusion inhibitor slow-release microsphere
CN102580056B (en) * 2011-12-16 2014-04-09 深圳市健元医药科技有限公司 Controlled-release injection containing antidiuresis components and preparation method thereof
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2809458T3 (en) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Liquid filled, abuse deterrent and immediate release dosage form
JP2017531026A (en) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Sustained release abuse deterrent liquid filler form
JP6776360B2 (en) * 2015-11-04 2020-10-28 ポステック・アカデミー‐インダストリー・ファウンデーションＰｏｓｔｅｃｈ Ａｃａｄｅｍｙ‐Ｉｎｄｕｓｔｒｙ Ｆｏｕｎｄａｔｉｏｎ A composition for skin penetration containing a cationic molecule transporter and a protein.
CN106729717A (en) * 2016-12-12 2017-05-31 深圳市健翔生物制药有限公司 The analogs of GLP 1 and ziconotide composition sustained-release microsphere preparation
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (en) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
WO1999055358A1 (en) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methods for treating hot flashes and gynaecomastia
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (en) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
US6180608B1 (en) * 1996-12-11 2001-01-30 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20030171296A1 (en) * 1996-12-11 2003-09-11 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP1398037A2 (en) * 1996-12-11 2004-03-17 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
WO1999055358A1 (en) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methods for treating hot flashes and gynaecomastia
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery

Also Published As

Publication number Publication date
WO2007021970A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007021970A3 (en) Stable pharmaceutical formulations and methods of use thereof
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2004074244A3 (en) Pyrimidine compounds
WO2007146248A3 (en) Stable laquinimod preparations
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2007087548A3 (en) Chemical compounds
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
WO2006096444A3 (en) Chemical compounds
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2002048148A3 (en) Pyrazolopyridine derivatives
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
MX2008001560A (en) Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds.
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
WO2009060952A1 (en) Novel preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIUGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 06801293

Country of ref document: EP

Kind code of ref document: A2